Adjuvant tislelizumab plus TACE in resected high-risk hepatocellular carcinoma (ATTACK): Preliminary analysis of a prospective cohort study

被引：0
|
作者：
Liu, J. [1 ]
Zeng, D. [2 ]
Cheng, Y. [1 ]
Li, Y. [1 ]
Zhang, M. [1 ]
Song, S. [2 ]
Huang, Y. [1 ]
机构：
[1] Shanghai Publ Hlth Clin Ctr, Hepatobiliary Surg Dept, Shanghai, Peoples R China
[2] Shanghai Publ Hlth Clin Ctr, Dept Pathol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.247
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227P
引用
收藏
页码：S1490 / S1490
页数：1
相关论文
共 50 条
  • [1] Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial
    Ma, T.
    Wen, L.
    Zhang, J.
    Zhang, Z.
    Zeng, Y.
    Wang, Y.
    Zheng, J.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1494 - S1494
  • [2] Adjuvant TACE plus lenvatinib as compared with TACE alone in patients with hepatocellular carcinoma at high risk of recurrence after surgery: A prospective controlled study.
    Zhang, Bin
    Jin, Renan
    Xu, Junjie
    Chen, Ming Yu
    Chen, Jiang
    Zhu, Hepan
    Cao, Jiasheng
    Song, Chao
    Yang, Zaibo
    Zhang, Yewei
    Liang, Xiao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 505 - 505
  • [3] Tislelizumab plus donafenib combined with transarterial chemoembolization in patients with resected high-risk hepatocellular carcinoma (TIDE): A prospective, single-arm, phase II trial
    Peng, W.
    Hao, Y.
    Wei, Y.
    Xie, F.
    Li, C.
    Zhang, X.
    Shen, J.
    Lu, W.
    Zhou, J.
    Wen, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S668 - S668
  • [4] Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors: A prospective, multicentric cohort study
    Su, J-Y.
    Liu, S.
    Xu, X-L.
    Ou, J-J.
    Li, L.
    Ma, Y-L.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1485 - S1486
  • [5] ADJUVANT IMMUNE CHECKPOINT INHIBITORS FOR HEPATOCELLULAR CARCINOMA PATIENTS WITH HIGH-RISK OF POSTOPERATIVE RECURRENCE: A PROSPECTIVE COHORT STUDY (PREVENT)
    Li, Le
    Huang, Shan
    Qi, Lu-Nan
    Xiang, Bang-De
    Ma, Liang
    Zhong, Jian-Hong
    HEPATOLOGY, 2023, 77 (05) : E132 - E133
  • [6] The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction
    Peng, N.
    Su, J-Y.
    Liu, S.
    Li, L.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1487 - S1487
  • [7] Tislelizumab plus tyrosine kinase inhibitor versus active surveillance in patients with ablated high-risk hepatocellular carcinoma: An open-label, parallel controlled, prospective cohort study
    Pan, Shida
    Wang, Siyu
    Tian, Jiahe
    Shen, Yingjuan
    Yang, Luo
    Liu, Xiaomeng
    Yu, Yingying
    Wang, Yilin
    Qiu, Qin
    Luan, Junqing
    Fan, Xing
    Meng, Fanping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
    Yang, Biao
    Jie, Luo
    Yang, Ting
    Chen, Mingyang
    Gao, Yuemei
    Zhang, Tian
    Zhang, Yuzu
    Wu, Hao
    Liao, Zhengyin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Wang, Kang
    Xiang, Yan-Jun
    Yu, Hong-Ming
    Cheng, Yu-Qiang
    Liu, Zong-Han
    Qin, Ying-Yi
    Shi, Jie
    Guo, Wei-Xing
    Lu, Chong-De
    Zheng, Ya-Xin
    Zhou, Fei-Guo
    Yan, Mao-Lin
    Zhou, Hong-Kun
    Liang, Chao
    Zhang, Fan
    Wei, Wen-Jing
    Lau, Wan Yee
    Li, Jing-Jing
    Liu, Yan-Fang
    Cheng, Shu-Qun
    NATURE MEDICINE, 2024, 30 (03) : 708 - +
  • [10] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Kang Wang
    Yan-Jun Xiang
    Hong-Ming Yu
    Yu-Qiang Cheng
    Zong-Han Liu
    Ying-Yi Qin
    Jie Shi
    Wei-Xing Guo
    Chong-De Lu
    Ya-Xin Zheng
    Fei-Guo Zhou
    Mao-Lin Yan
    Hong-Kun Zhou
    Chao Liang
    Fan Zhang
    Wen-Jing Wei
    Wan Yee Lau
    Jing-Jing Li
    Yan-Fang Liu
    Shu-Qun Cheng
    Nature Medicine, 2024, 30 : 708 - 715
12345